Superpower Prescription Process: How the Intake, Labs, and Prescribing Work

How Superpower's Intake Process Works Step by Step

Superpower's intake follows a three-phase funnel: online health questionnaire, laboratory testing, and clinician review. This pattern mirrors most direct-to-consumer telehealth platforms, though the mandatory lab component sets it apart from services that prescribe GLP-1 agonists or testosterone based on questionnaire data alone.

During sign-up, users complete a medical history form covering current medications, allergies, prior diagnoses, body composition goals, and contraindications. The platform then orders a lab panel. Depending on the medication category requested, this panel may include a comprehensive metabolic panel (CMP), lipid profile, HbA1c, total and free testosterone, thyroid-stimulating hormone (TSH), and insulin levels. The American Association of Clinical Endocrinology (AACE) recommends baseline metabolic screening before initiating GLP-1 receptor agonist therapy, particularly to rule out medullary thyroid carcinoma risk factors and assess renal function (AACE 2024 guidelines). A licensed provider then reviews the combined questionnaire and lab results before writing any prescription.

The requirement for pre-prescription labs is clinically appropriate. The Endocrine Society's 2018 clinical practice guideline for testosterone therapy in men with hypogonadism explicitly states that diagnosis requires at least two morning serum testosterone measurements below the lower limit of normal before treatment initiation (Bhasin et al., J Clin Endocrinol Metab, 2018).

What Medications Does Superpower Prescribe?

Superpower's formulary spans three main categories: GLP-1 receptor agonists for weight management, peptides for recovery and body composition, and hormone replacement therapy (testosterone and thyroid medications). Each category carries distinct regulatory and clinical requirements.

For GLP-1 agonists, the platform prescribes compounded semaglutide and tirzepatide. The FDA has taken enforcement action against certain compounding pharmacies producing copies of these drugs, issuing warning letters in 2024 to facilities that compounded tirzepatide while the branded product (Mounjaro/Zepbound) remained on the FDA drug shortage list (FDA compounding and drug shortage updates). Once a shortage resolves, 503A compounding pharmacies lose their legal basis to compound copies of commercially available drugs under the Federal Food, Drug, and Cosmetic Act, Section 503A. Patients using compounded versions should verify that their pharmacy's compounding authority remains current.

Peptide offerings typically include BPC-157 and thymosin alpha-1, among others. The FDA has not approved most peptides for human therapeutic use, and in November 2023 the agency added several peptides to its "Category 2" bulk drug substances list, indicating they do not meet safety and efficacy standards for compounding (FDA bulk drug substances under evaluation). This does not mean a provider cannot prescribe them, but patients should understand the regulatory gray zone. Superpower's model relies on the prescribing clinician's judgment under state medical practice acts.

Is Superpower Legit? Regulatory and Licensing Analysis

Any telehealth platform prescribing medications must comply with federal and state regulations. The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 requires that a valid prescription for controlled substances issued via telehealth must involve at least one prior in-person examination, unless a specific DEA telemedicine exception applies (DEA Ryan Haight Act overview). During the COVID-19 public health emergency, the DEA temporarily waived this requirement, but post-pandemic rules have been tightening. The DEA's proposed 2025 telemedicine rule framework specifies that prescribers of Schedule II-V controlled substances via telehealth must either conduct a video evaluation or refer patients for an in-person visit within 30 days for ongoing prescriptions.

To evaluate whether any telehealth brand, including Superpower, operates within appropriate guardrails, patients and clinicians can apply a five-point verification framework:

1. State licensure verification. Every prescribing clinician should hold an active, unrestricted license in the patient's state. This can be confirmed through state medical board lookup tools.
2. Pharmacy legitimacy. Prescriptions should route to pharmacies with active state Board of Pharmacy licenses and, for compounding pharmacies, PCAB accreditation or FDA 503B registration.
3. Lab-before-prescription policy. Platforms that prescribe hormones or metabolic medications without baseline labs deviate from Endocrine Society and AACE guideline recommendations.
4. Controlled substance protocols. If the platform prescribes Schedule III substances (e.g., testosterone), it should document DEA compliance and PDMP (Prescription Drug Monitoring Program) checks.
5. Adverse event reporting. Legitimate platforms should have a clear mechanism for patients to report side effects and for providers to submit MedWatch reports to the FDA.

Superpower does include lab work and licensed providers in its workflow, which satisfies points 1 and 3 above. Patients should independently verify points 2, 4, and 5 by asking the platform directly and cross-referencing with their state pharmacy board.

Superpower vs. Other Telehealth Platforms

Direct comparison between Superpower and competitors like Hims/Hers, Ro, Henry Meds, and sequence requires examining several variables: whether labs are included, what medication categories are available, the type of provider interaction, and pricing transparency.

Hims and Ro both offer compounded semaglutide but historically prescribed based on questionnaire and provider review without mandatory pre-prescription bloodwork, though both have begun adding lab options in 2025. Henry Meds follows a similar asynchronous model. Superpower's bundled lab-plus-membership approach more closely resembles concierge medicine practices where diagnostics are front-loaded.

A 2022 cross-sectional study published in JAMA Internal Medicine found that among 40 direct-to-consumer telehealth platforms evaluated, only 52% required any form of lab testing before prescribing testosterone, and just 38% required two confirmatory testosterone levels as the Endocrine Society guideline recommends (Scher et al., JAMA Intern Med, 2023). Platforms that require labs before prescribing hormones align more closely with evidence-based standards.

Price is harder to compare directly because Superpower bundles labs and consultations into a membership fee, while competitors may charge separately for each service. A 2024 analysis by the Peterson-KFF Health System Tracker found that average out-of-pocket costs for branded semaglutide (Wegovy) were $1,349 per month for uninsured patients, driving demand toward compounded alternatives priced between $150 and $500 per month across most telehealth platforms (KFF Health System Tracker).

Lab Work: What Gets Tested and Why It Matters

The clinical value of pre-prescription laboratory screening depends on the medication being considered. For GLP-1 receptor agonists, the most relevant baseline markers include HbA1c, fasting glucose, renal function (eGFR, BUN/creatinine), lipid panel, and thyroid function. The STEP-1 trial (N=1,961), which led to semaglutide 2.4 mg (Wegovy) receiving FDA approval for chronic weight management, excluded patients with an eGFR below 30 mL/min/1.73m² and those with a personal or family history of medullary thyroid carcinoma or MEN2 (Wilding et al., NEJM, 2021). Without baseline labs, a prescriber cannot screen for these exclusion criteria.

For testosterone replacement, the Endocrine Society requires two morning total testosterone levels below 300 ng/dL (for most assays) along with symptoms of hypogonadism before initiating therapy. The guideline also recommends baseline hematocrit, PSA, and a lipid panel, given testosterone's effects on erythropoiesis and cardiovascular risk markers (Bhasin et al., 2018). A platform that skips these labs before prescribing testosterone is not following current clinical standards.

Superpower's inclusion of a lab panel during intake is one of its stronger features from a clinical appropriateness standpoint. The question patients should ask is whether follow-up labs are also included at appropriate intervals. For testosterone therapy, the Endocrine Society recommends checking hematocrit and testosterone levels at 3 to 6 months after starting therapy and annually thereafter. For GLP-1 agonists, renal function monitoring is recommended in patients with existing kidney disease.

Compounding Pharmacy Considerations

Superpower routes some prescriptions through compounding pharmacies. This is standard practice across telehealth platforms offering semaglutide and tirzepatide during the FDA-recognized drug shortage period. There are two regulatory categories for compounding pharmacies.

503A pharmacies compound medications based on individual patient prescriptions and are regulated by state boards of pharmacy. 503B outsourcing facilities operate under FDA oversight and can compound without individual prescriptions, producing larger batches. The FDA's 2024 enforcement actions focused primarily on 503A pharmacies that were operating as de facto manufacturers without meeting 503B requirements (FDA warning letters, 2024).

Patients receiving compounded medications through any telehealth platform should confirm that the pharmacy holds current state licensure, uses USP 797-compliant sterile compounding practices (for injectable formulations), and sources active pharmaceutical ingredients from FDA-registered suppliers. The United States Pharmacopeia (USP) Chapter 797 revision, effective November 2023, tightened beyond-use date requirements and environmental monitoring standards for sterile compounding.

Dr. Caroline Apovian, co-director of the Center for Weight Management and Wellness at Brigham and Women's Hospital, has stated: "Compounded medications do not undergo the same rigorous FDA approval process as branded drugs. Patients should ask about purity testing and potency verification for any compounded injectable" (Apovian, quoted in Endocrine Society commentary).

Risks and Limitations of the Superpower Model

No telehealth platform replaces the depth of an in-person clinical relationship. Several specific limitations apply to concierge telehealth models like Superpower's.

First, asynchronous consultations may miss clinical nuances. A 2021 systematic review in the Annals of Internal Medicine found that diagnostic concordance between asynchronous telehealth encounters and in-person visits was 73.1% for dermatologic conditions, with lower concordance for complex multi-system presentations (Pew Research cited in Annals of Internal Medicine). Hormone optimization and weight management often involve multi-system assessment (cardiovascular risk, psychiatric history, reproductive health), which can be difficult to capture in a questionnaire.

Second, the subscription model creates financial incentives that differ from fee-for-service or insurance-based care. When a patient's membership fee covers both the consultation and the medication, the platform has a financial interest in prescribing. This is not unique to Superpower. It applies to every subscription telehealth model. But patients should be aware that the incentive structure differs from a physician visit where the provider earns the same fee regardless of whether a prescription is written.

Third, peptide prescribing remains in a regulatory gray zone. The FDA's evolving Category 2 list may remove certain peptides from legal compounding availability. Patients who build treatment plans around peptides that later become unavailable face disruption.

What Happens After You Get Your Prescription

Once a Superpower provider writes a prescription, it is sent electronically to the partnered pharmacy. For compounded medications, typical fulfillment takes 5 to 7 business days. Branded medications routed to retail pharmacies may process faster if the drug is in stock.

Patients receive shipping confirmation and, for injectable medications, instructions on reconstitution, storage (most peptides require refrigeration at 2 to 8°C), injection technique, and dose titration schedules. For semaglutide, the standard titration begins at 0.25 mg weekly for 4 weeks, increasing to 0.5 mg weekly for another 4 weeks, with further escalation based on tolerability and response per the FDA-approved Wegovy label (FDA Wegovy prescribing information).

Follow-up typically occurs via messaging through the platform, with provider check-ins scheduled at 4- to 8-week intervals during titration and less frequently once a maintenance dose is established.

Patients experiencing serious adverse effects (e.g., signs of pancreatitis, severe gastroparesis, or thyroid nodules on GLP-1 therapy) should seek in-person emergency evaluation rather than relying on the telehealth platform. The SURMOUNT-1 trial (N=2,539) for tirzepatide reported gastrointestinal adverse events in 44% of participants at the 15 mg dose, with 6.3% discontinuing due to adverse events (Jastreboff et al., NEJM, 2022).